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Abstract
Alterations of DNA methylation play an important role in gliomas. In a genome-wide screen, we identified a CpG-rich
fragment within the 5′ region of the tumor necrosis factor receptor superfamily, member 11A gene (TNFRSF11A) that
showedde novomethylation in gliomas. TNFRSF11A, also knownas receptor activator of NF-κB (RANK), activates several
signaling pathways, such as NF-κB, JNK, ERK, p38α, and Akt/PKB. Using pyrosequencing, we detected RANK/
TNFRSF11A promoter methylation in 8 (57.1%) of 14 diffuse astrocytomas, 17 (77.3%) of 22 anaplastic astrocytomas,
101 (84.2%) of 120 glioblastomas, 6 (100%) of 6 glioma cell lines, and 7 (100%) of 7 glioma stem cell–enriched glio-
blastoma primary cultures but not in four normal white matter tissue samples. Treatment of glioma cell lines with the
demethylating agent 5-aza-2′-deoxycytidine significantly reduced the methylation level and resulted in increased RANK/
TNFRSF11AmRNA expression. Overexpression of RANK/TNFRSF11A in glioblastoma cell lines leads to a significant re-
duction in focus formation and elevated apoptotic activity after flow cytometric analysis. Reporter assay studies of trans-
fected glioma cells supported these results by showing the activation of signaling pathways associated with regulation
of apoptosis. We conclude that RANK/TNFRSF11A is a novel and frequent target for de novo methylation in gliomas,
which affects apoptotic activity and focus formation thereby contributing to the molecular pathogenesis of gliomas.
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Introduction
Gliomas are the most common primary brain tumors in adults, with
glioblastoma of World Health Organization (WHO) grade 4 being
the most frequent and most malignant type of glioma. The incidence
rate of primary glioblastoma is 3.18 per 100,000 person years, age
adjusted to the 2000 US standard population. Gliomas can develop
at any age with a peak incidence between 65 and 84 years. Glio-
blastomas (GBMs) are highly invasive and respond poorly to radia-
tion therapy as well as most forms of chemotherapy. It, therefore, has
a dismal prognosis with a median survival time of less than 12 months
as shown in a population-based study [1,2]. Primary glioblastomas are
characterized by multiple genetic alterations, commonly including loss
of heterozygosity (LOH) on chromosome 10, EGFR amplification and
overexpression, CDKN2A deletion and PTEN mutation [1,2]. Only
5% of glioblastomas develop through progression from preexisting as-
trocytomas of WHO grade 2 or 3 [3]. These so-called secondary glio-
blastomas typically lack EGFR amplification but frequently carry TP53
mutations. Recently, somatic mutations of the IDH1/IDH2 genes
have been reported in most diffuse astrocytic and oligodendroglial tu-
mors as well as secondary glioblastomas. These mutations, however, are
rare in primary glioblastomas [4]. Interestingly, IDH1 mutation seems
to be associated with increased DNA methylation at 5′-CpG islands
of multiple genes, the so-called CpG island methylator phenotype [5].
To identify novel glioma-associated candidate genes subjected to epi-
genetic regulation, we applied a genome-wide methylation analysis
using the differential methylation hybridization (DMH) technology.
From this approach, we identified several novel candidate tumor
suppressor genes showing altered promoter methylation patterns in
gliomas [6]. Here, we report on the epigenetic inactivation of the
RANK/TNFRSF11A gene in gliomas and derived cell lines. This gene
encodes a type 1 membrane protein that, after binding its ligand
RANKL, activates signaling pathways such as NF-κB, JNK, ERK,
p38, and Akt/PKB, through TRAF protein phosphorylation. RANK/
TNFRSF11A signaling is largely considered to be growth promoting
and apoptosis reducing such as the effects observed in osteoclasts [7–
9]. However, there is increasing evidence that in other cell systems the
activity of RANK/TNFRSF11A may in fact trigger apoptosis and sup-
press proliferation [10,11]. Our data indicate that epigenetic silencing
of RANK/TNFRSF11A was confirmed by treatment of glioma cells
with demethylating agent 5-aza-2′-deoxycytidine, which resulted in
increased expression of the corresponding transcript. Transient as well
as stable transfection of RANK/TNFRSF11A into established glio-
blastoma cell lines resulted in a significant reduction of focus formation
and increased apoptosis. Reporter assays of transfected glioblastoma
cells reveal an up-regulation of NF-κB signaling but also unmask an
activation of distinct signaling pathways associated with the regulation
of apoptosis.
Materials and Methods
Tumor Samples and Cell Lines
We investigated glioma tumor specimens from 156 patients includ-
ing 97 with primary glioblastomasWHO grade IV (pGBMIV), 23 with
secondary glioblastomas WHO grade IV (sGBMIV), 22 with anaplastic
astrocytomas WHO grade III (AAIII), and 14 with diffuse astrocytomas
WHO grade II (AII). Primary as well as recurrent tumor samples of
three patients were investigated. The patients included 63 women and
86 men. The mean age at surgery was 55 years (range, 24-80 years).
All tumors were classified according to the WHO classification of
tumors of the central nervous system [12]. Histologic assessment con-
firmed that all specimens used for extraction of nucleic acids consisted
of at least 80% tumor cells. DNA and RNA were extracted from un-
fixed frozen tumor tissue as reported [13]. In brief, tumor samples
were homogenized in 6 ml of 4 M guanidine isothiocyanate solu-
tion. The homogenate was then layered over 4 ml of CsCl and ultra-
centrifuged at 170,000g for 16 hours. The RNA was recovered as a
pellet and dissolved in diethylpyrocarbonate-treated water containing
the RNase inhibitor RNasin (Promega, Mannheim, Germany). The
DNA was purified from the CsCl phase using proteinase K digestion
followed by phenol/chloroform extraction. Four normal white matter
tissue samples were used to extract DNA as reference tissue for the
DMH and focused methylation analyses. Glioma cell lines A172,
U373MG, T98G, A178, U87MG, and LN229 were obtained from
the LICR (San Diego, CA), and identities were confirmed by STR
DNA profiling of 15 loci plus sex-determining marker amelogenin
(Genetica DNA Laboratories, Inc, Cincinnati, OH). Seven stem cell–
enriched primary glioblastoma cultures (15z, 21z, 25z, 35z, 46z, 78z,
and 106z) were also included in our study [14]. All tissue samples were
used in an anonymous manner as approved by the local ethics com-
mittee at Heinrich Heine University Düsseldorf and University Bonn.
DMH Analysis
The DMH procedure was performed as described [6,15]. CpG-rich
DNA fragments were isolated from the human CGI (CpG island)
library and screened for the presence of BstUI (NEB, Beverly, MA)
and HpaII (NEB) restriction sites. A total of 16,000 suitable fragments
were polymerase chain reaction (PCR) amplified using plasmid primer
and spotted onto UltraGAPS microarrays (Corning, Acton, MA). For
amplicon generation, 2 μg of genomic DNA of tumor and normal
brain samples (white matter) was digested with MseI (NEB) accord-
ing to the manufacturer’s protocol. After ligation of linker H12/
H24, fragments were digested with methylation-sensitive restriction
enzymes BstUI and HpaII and amplified for 20 cycles with H24 as
primer. PCR fragments were labeled by direct incorporation of Cy3-
dCTP (normal brain) and Cy5-dCTP (tumor) using fluorescent dyes
(Amersham, Buckinghamshire, United Kingdom) and the Klenow
fragment (Invitrogen, Carlsbad, CA). Labeled amplicons were purified
with Microcon YM-30 columns (Millipore, Bedford, MA), and equal
amounts of Cy3 and Cy5 label and 20 μg of human CotI DNA were
combined for hybridization on DMH microarrays. Hybridization and
analysis procedure were carried out as described [6,15]. Data from
single-copy sequences were normalized and loci with a Cy5/Cy3 ratio
greater than 2 were scored as hypermethylated.
Analysis of the RANK/TNFRSF11A 5′-CpG Island
Methylation Status by Pyrosequencing
Genomic DNA of gliomas, glioblastoma cell lines, stem cell–
enriched primary glioblastoma cultures, and nonneoplastic white
matter tissue was treated with sodium bisulfite using the EpiTect
Bisulfite kit (Qiagen, Hilden, Germany). PCR products of RANK/
TNFRSF11A containing 14 putative CpG methylation sites were
amplified from sodium bisulfite–converted DNA using the primer
RANK1 fw-5′-ggtaaggtaggagttagtgt-3′ and the biotinylated reverse
primer RANK-Bio rev-5′-aatacccaaactcccctaattta-3′. The pyrosequenc-
ing primer was RANK-Pyro-5′-ggtaatttagggttggtttt-3′. Pyrosequencing
was performed using the PyroMarkGold Reagents (Qiagen) on the
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Pyromark Q24 instrument (Qiagen) according to the manufacturer’s
instructions. Pyrogram outputs were analyzed using the PyroMark
Q24 software.
Tissue Culture of Glioblastoma Cell Lines and Treatment
with 5-Aza-2′-deoxycytidine
Glioblastoma cell lines A172 and U373MG were cultured as de-
scribed [16]. To induce demethylation, cell lines were grown in the
presence or absence of 1 to 5 μM 5-aza-2′-deoxycytidine (Sigma,
St. Louis, MO). Medium was renewed daily. After 3 days, DNA
and total RNA were extracted for RANK/TNFRSF11A methylation
and expression analysis. This experiment was performed in triplicates.
RANK/TNFRSF11A mRNA Expression Analysis by
Real-time Reverse Transcription–PCR
For complementary DNA (cDNA) synthesis, 1 μg of total RNA, ran-
dom hexamers, and SuperScript II Reverse Transcriptase (Invitrogen)
was used according to the instructions of the manufacturer.
RANK/TNFRSF11A expression was investigated by real-time reverse
transcription–PCR (RT-PCR) using the ABI PRISM 5700 sequence
detection system (Applied Biosystems). The transcript level of RANK/
TNFRSF11A was normalized to the transcript level of ADP-ribosylation
factor 1 (ARF1; GenBank accession no. M36340) [17]. To ensure that
high-quality RNA was used for expression analysis, only tumors with
C t values of at most 30 cycles for the control locus ARF1 were used
(range, 18.2-27.5). Primer sequences were RANK/TNFRSF11A-RT-F,
5′-tcaacaaggacacagtgtgc-3′, and RANK/TNFRSF11A-RT-R, 5′-
tttggtggttttctagctgg-3′, resulting in a 181-bp fragment and ARF1-F,
5′-gaccacgatcctctacaagc-3′, and ARF1-R, 5′-tcccacacagtgaagctgatg-3′,
resulting in a 111-bp fragment. RNA of normal white matter tissue
and commercially available adult human brain RNA of corpus callosum,
temporal lobe, parietal lobe, frontal lobe, and occipital lobe (BioChain
Institute, Inc, Hayward, CA) was used as controls. Expression levels
of individual tumors and cell lines are given as ratio = 2−ΔΔC t. Because
of the limited availability of RNA expression analysis were performed
in duplicates.
RANK/TNFRSF11A Information from TCGA and
REMBRANDT Platform Analyses
The TCGA dat aportal does not show information on methylation
or expression of RANK/TNFRSF11A in glioblastomas when assessing
the TCGA data on the CGWB (The Cancer Genome Workbench) at
the National Institutes of Health server https://cgwb.nci.nih.gov/ and
https://cgwb.nci.nih.gov/cgi-bin/srstuff?prjid=41&db=hg18&op=
methyl in March 2012 [1]. The REMBRANDT database (NCI2005;
REMBRANDT version 1.5; http://rembrandt.nci.nih.gov/) contained
expression data of RANK/TNFRSF11A. The Kaplan-Meier Survival
plot of this data (343 glioma), however, does not show any significant
correlation with up- or down-regulation of RANK/TNFRSF11A.
RANK/TNFRSF11A Cloning and Transfection
RANK/TNFRSF11A plasmid was purchased from OriGene
(Rockville, MD) and subcloned into pcDNA4/myc-His expression
vector (Invitrogen). U373MG and A172 cells were transfected by
lipofection (FuGENE 6; Roche, Mannheim, Germany) and selected
by adding 240 to 320 μg/ml zeocin (Invitrogen) to the growth medium
after 24 hours. Approximately 2 weeks later, zeocin-resistant colonies
were trypsinized, and total RNA were extracted for RANK/TNFRSF11A
expression analysis. Assays were carried out at least in triplicates.
Colony Formation Assay
For colony formation assays, cells (2 × 105/well) were seeded in 12-well
tissue culture plates and transfected with either RANK-pcDNA4/myc-
His plasmid or pcDNA4/myc-His control vector (0.8 μg each) using
FuGENE 6 transfection reagent (FuGENE 6; Roche). At 24 hours after
transfection, cells were collected, seeded in 10-cm dishes, and exposed
to 240 μg/ml (A172) or 320 μg/ml (U373MG) zeocin (Invitrogen) for
a total of 14 days. Cells were fixed and stained in 20% methanol and
crystal violet, and colonies with more than 50 cells were counted. Assays
were carried out at least in triplicates.
Measurement of Cellular Proliferation and Viability by
Flow Cytometry
U373MG cells stably or transiently expressing RANK-pcDNA4/
myc-His plasmid or pcDNA4/myc-His control vector (in case of tran-
sient transfection cells were cotransfected with pMAX GFP) were
serum starved for 24 hours. Flow cytometric immunophenotyping
was performed as described [18,19] with an Alexa Fluor 647–labeled
phospho-(Ser10)-histone H3 antibody (1:20; Cell Signaling Technol-
ogy, Frankfurt am Main, Germany) staining proliferating cells and a
phycoerythrin-labeled cleaved poly(ADP-ribose) polymerase (PARP)
(Asp214) antibody (1:5; BD Biosciences, Heidelberg, Germany) to
detect apoptotic cells [19–22].
At least 100,000 events were recorded per experiment. For transient
transfection, only GFP-positive single cells were included in the analy-
sis. Each experiment was carried out at least in triplicates.
Multipathway Reporter Array
U373MG cells overexpressing RANK-pcDNA4/myc-His plasmid or
pcDNA4/myc-His control vector were reverse transfected with each of
the reporter assays from the 45-Pathway reporter Array plate (SA Bio-
sciences, Frederick, MD) using X-tremeGENE HP DNA transfection
reagent (Roche) [23]. The reporter assay consists of a mixture of an
inducible transcription factor responsive firefly luciferase reporter and
constitutively expressing renilla construct. A mixture of noninducible
firefly luciferase reporter and constitutively expressing renilla construct
and a mixture of a constitutively expressing GFP construct constitutively
expressing firefly luciferase and renilla luciferase construct was included
as negative and positive controls. Reverse transfection was performed fol-
lowing the manufacturer’s recommendation (SA Biosciences). After
48 hours, luciferase assay was performed using the Dual-Luciferase Re-
porter Assay following the manufacturer’s protocol (Promega, Madison,
WI), and results are expressed as fold change. The fold change was cal-
culated by dividing the normalized luciferase activities of each pathway-
focused reporter reverse transfected with U373MG cells overexpressing
RANK-pcDNA4/myc-His plasmid by the normalized luciferase activity
of each pathway-focused reporter reverse transfected with the negative
control (U373MG cells expressing pcDNA4/myc-His plasmid). Report-
ers showing two-fold or higher changes up or down in relative luciferase
units were considered as upregulated or downregulated, respectively.
Experiments were performed in duplicates and analyzed using GloMax
96 Microplate Luminometer (Promega).
Statistical Analysis
All statistical analyses, including t test, Fisher exact test, and Mann-
Whitney U test were carried out with the GraphPad Prism software
(version 5; GraphPad Software, La Jolla, CA).
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Results
Aberrant Methylation within the 5′-CpG Island of
RANK/TNFRSF11A
Using DMH analysis, we identified a CpG-rich fragment that was
frequently hypermethylated in gliomas. This fragment is located within
the 5′-CpG island 120 (CpG:120 chr18:59992070-59993556) start-
ing at 477 bp upstream of the first exon of the receptor activator of
NF-κB/tumor necrosis factor receptor superfamily 11A gene (RANK/
TNFRSF11A; Figure 1). To determine the frequency and extent of
de novomethylation within this fragment, pyrosequencing analyses were
performed on 156 gliomas, 4 cerebral white matter samples, 6 glioma
Figure 1. Localization of the investigated DNA fragment within the CpG island at chromosome 18q21.33 (59991900-59992679). The
sequence investigated by pyrosequencing, and the ATG start codon is indicated. Below, details of two representative pyrograms within
the 5′ upstream region of RANK/TNFRSF11A are shown. The glioblastoma sample GBM042 (A) shows strong methylation, whereas low
methylation levels were found in normal white matter tissue (B).
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cell lines, and 7 stem cell–enriched glioma primary cultures. Figure 1
shows a section of representative pyrograms of CpG sites 1 to 14 within
the investigated region in a primary glioblastoma (GBM042) and a nor-
mal brain white matter sample (NB2). The tumor sample carried a high
content of methylated alleles with most CpG sites being strongly meth-
ylated, whereas white matter showed low levels of methylation in this
region. Samples were scored methylated if they exceeded the two-fold
SD of white matter control samples (20.3%). De novo methylation of
RANK/TNFRSF11A was found in 8 (57.1%) of 14 AII, 17 (77.3%)
of 22 AAIII, 20 (87%) of 23 sGBMIV, 81 (83.5%) of 97 pGBMIV,
6 (100%) of 6 glioma cell lines, and 7 (100%) of 7 stem cell–enriched
glioma primary cultures but not in four normal white matter samples
(Table W1). The overall methylation level as determined by taking
themean of the arithmeticmeans of pyrosequencingmethylation grades
of CpG sites was 25.4% in AII, 28.9% in AAIII, 40.2% in sGBMIV,
33.3% in pGBMIV, 50.3% in stem cell–enriched glioma primary cul-
tures, 74.2% in glioblastoma cell lines, and 11.9% in normal white
matter (Figures 2A, W1, and Table W1). These data demonstrate
that methylation of RANK/TNFRSF11A is significantly more frequent
in high-grade gliomas (Fisher exact test, P = .0246) compared with
low-grade astrocytomas. Furthermore, the mean methylation levels of
glioblastoma WHO grade IV are significantly stronger than those of
low-grade astrocytomas WHO grade II and anaplastic astrocytomas
WHO grade III (Table W1, t test: AII + AAII vs pGBMIV, P = .026;
AII + AAIII vs sGBMIV, P = .0035), whereas AII and AAIII do not
differ significantly (t test, P = .3767). This was confirmed in primary
and recurrent tumors from three individual patients whereby the
precursor lesions were of lower grade than the subsequent secondary
glioblastomas. The observed methylation levels were three- to five-fold
higher in the secondary glioblastomas than in the corresponding primary
astrocytomas WHO grade 2 (t test, P = .0264; Figure 2B). The inves-
tigation of seven stem cell–enriched primary glioblastoma cultures by
pyrosequencing showed even higher methylation levels (50.3%) espe-
cially surrounding the p53 binding site (Figure W1). This indicates
that this epigenetic modification targets those cells that are considered
to be the drivers of tumor growth and capable of forming gliomas in
xenografted animals.
Expression Analyses of RANK/TNFRSF11A in Glioma Tissues
The mRNA expression of RANK/TNFRSF11A and the housekeeping
gene ARF1 was investigated in 77 primary glioma tissues, 6 glioblastoma
cell lines, and 9 normal white matter tissues (Figures 3A andW4). Com-
pared with the normal brain tissues, there is a trend toward reduced
transcript levels from diffuse astrocytomas, anaplastic astrocytomas to
glioblastomas. In each group, however, there were few samples showing
comparably high transcript levels. All investigated glioblastoma cell
lines showed reduced RANK/TNFRSF11A transcript levels. Dividing
the 77 samples into a methylated and an unmethylated group (samples
were scored methylated if they exceeded the two-fold SD of white
matter control samples [20.3%]) revealed a significant difference in the
expression levels (Mann-Whitney U test, P = .0159; t test, P = .0017).
Demethylation and Expression Analyses of RANK/
TNFRSF11A in Glioblastoma Cell Lines
TNFRSF11A/RANK mRNA expression was downregulated in the
glioblastoma cell lines A172 and U373MG. After treating the cells
with 5-aza-2′-deoxycytidine, 1.7- and 3.5-fold increases in transcript
levels were detected (Figure 3B). Bisulfite sequencing confirmed that
5-aza-2′-deoxycytidine treatment resulted in demethylation of the
investigated region (Figure W2). These data indicate that aberrant
5′-CpG island methylation contributes to the down-regulation of
RANK/TNFRSF11A transcription in glioblastoma cell lines.
Figure 2. Average methylation level of 156 primary glioma tissues, glioblastoma cell lines, stem cell–enriched primary glioblastoma
cell cultures, and normal white matter tissues within the investigated region of RANK/TNFRSF11A (A). Heat map of quantitative methyla-
tion data of the 14 investigated CpG sites within the RANK/TNFRSF11A CpG island in three patients, for which tissue from the initial
low-grade glioma and the high-grade relapse tumor were available. The color code shows the methylation range (0%-60%) (B).
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Functional Analysis of RANK/TNFRSF11A in Glioma Cells
To study the influence of RANK/TNFRSF11A expression on growth
and apoptotic activity of glioblastoma cells in vitro, we overexpressed
RANK/TNFRSF11A in the glioblastoma cell lines U373MG and
A172. RANK/TNFRSF11A expression was monitored by real-time
RT-PCR (Figure W3). In colony formation assays, an average of 32
and 9 colonies formed in U373MG and A172 cells transfected with
RANK/TNFRSF11A, in comparison to an average of 195 and 51 colo-
nies in the control cells (Figure 4A). Thus, expression of RANK/
TNFRSF11A led to an 84% and 82% decrease in colony number (t test,
P < .0001 in U373MG cells and P = .0193 in A172 cells, respectively).
To further investigate the functional role of RANK/TNFRSF11A
on cellular proliferation and apoptosis, we performed flow cytometric
analyses using antibodies against Ser10-phosphorylated Histone H3
and PARP (Asp214). The apoptotic cellular population of U373MG
cells transiently transfected with RANK/TNFRSF11A was significantly
increased by 124% in U373MG cells (t test, P < .0001), when com-
pared with the respective control cells, whereas the proliferation was
slightly increased by 26% (Figure 4B). This experiment was repeated
with U373MG cells stably expressing RANK/TNFRSF11A with sim-
ilar results. The functional data indicate a role of RANK/TNFRSF11A
in the regulation of apoptosis in glioblastoma cells. Because no signifi-
cant reduction of proliferation was observed in flow cytometric analysis,
it is likely that the reduced focus formation is not due to a reduced
proliferative potential but rather to an increased apoptotic activity in
the RANK/TNFRSF11A-transfected glioblastoma cells.
Activity of Downstream Signaling Pathways
To identify molecular pathways responsible for transmitting signals
downstream of RANK/TNFRSF11A, we have used a signal trans-
duction reporter assay that allows the comprehensive analysis of 45 sig-
naling pathways. U373MG cells overexpressing RANK-pcDNA4/
myc-His plasmid or pcDNA4/myc-His control vector were reverse
transfected with each of the 45 reporter assays from the array plate.
Our results indicate that overexpression of RANK/TNFRSF11A up-
regulates amino acid response, cAMP/PKA (CRE), hypoxia (HIF),
NF-κB, Oct4, and Wnt (TCF/LEF) signaling while downregulating
androgen and STAT3 signaling in U373MG cells (Figure 5).
Relationship between Molecular Findings and Clinical Data
The comparison of RANK/TNFRSF11A methylation and clinical
showed no significant correlation with survival data of pGBMIV pa-
tients (P = .355).
Mutation of the TP53 gene was assessed in 48 glioma samples
(9 AAIII, 12 sGBMIV, and 27 pGBMIV) and was shown in 18
(40.9%) of the tumors studied, including 4 AAIII, 8 sGBM, and
6 pGBM. TP53mutation was not associated with RANK/TNFRSF11A
methylation (Fisher exact test, P = .28). IDH1 mutations identified in
5 AII, 15 AAIII, 17 sGBMIV, and 9 pGBMIV do not correlated with
RANK/TNFRSF11A methylation (Fisher exact test, P = 1.0).
Discussion
Our global approach to identify novel genes silenced by promoter meth-
ylation in human gliomas uncovered the RANK/TNFRSF11A gene lo-
cated on chromosome 18q21.33. The gene encodes a 616-amino acid
transmembrane receptor that belongs to the TNFR family [24].
Binding of the ligand RANKL results in intracellular signal trans-
duction through several TRAFs (TNF receptor–associated factor) and
may lead to the activation of various signaling pathways, including the
NF-κB, MAPK (JNK, p38, ERK) and PI3K/AKT cascades [7,9].
RANK/TNFRSF11A and RANKL are known to play a key role in the
differentiation, activation, and survival of osteoclasts. The balance be-
tween RANK/TNFRSF11A, RANKL, and its decoy receptor OPG is
pivotal for bone biology, but they are also involved in other biologic sys-
tems, for example, the immune and vascular systems [8,9]. Furthermore,
there is also evidence that this receptor might have growth-suppressive
and proapoptotic functions in other cell types [11,24]. Therefore, we
decided to investigate the epigenetic regulation of this gene in gliomas
and to elucidate its functional implications in glioma cells.
To our knowledge, this is the first study demonstrating epigenetic
regulation of RANK/TNFRSF11A in cancer. We investigated the
methylation status of RANK/TNFRSF11A in 156 astrocytic gliomas
of different malignancy grades, established glioma cell lines and pri-
mary glioblastoma stem cell–enriched cultures. Our data revealed
frequent hypermethylation of the promoter CpG island in both
primary glioma tissues and cultured glioma cells. A significant in-
crease in the overall methylation level and in the number of affected
Figure 3. Relative transcript levels of RANK/TNFRSF11A (RANK/
TNFRSF11A/ARF1) analyzed by real-time RT-PCR in gliomas, glio-
blastoma cell lines, and normal white matter tissue (A). Relative
transcript levels of RANK/TNFRSF11A in glioblatoma cell lines with
(□) or without (▪) 1 and 5 μM 5-aza-2′-deoxycytidine treatment (B).
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samples with WHO grade suggests a progression-associated advantage
in growth or clonal expansion of glioma cells containing methylated
RANK/TNFRSF11A alleles. Although the quantitative methylation
analysis of the primary tumor tissues focused on a region adjacent to
a putative p53 binding site in the RANK/TNFRSF11A promoter,
there was a spread of methylation extending beyond this region in
stem cell–enriched primary cultures and in established glioma cell lines.
The fact that most of the investigated stem cell–enriched glioblastoma
cultures contained strongly methylated RANK/TNFRSF11A alleles
argues for an important role of this epigenetic modification in the molec-
ular pathogenesis of glioblastomas. The strong methylation adjacent to
the putative p53 binding site suggests that RANK/TNFRSF11A tran-
scription might be altered in gliomas by perturbing p53 binding to the
respective consensus sequence. Alternatively, the inactivation of p53 by
somatic mutations, which are often seen in AII, AAIII, and sGBMIV
gliomas, might prevent the binding of the protein to this site, thereby
allowing CpG methylation to occur. A recent study indicated that a
large fraction of diffuse and anaplastic gliomas as well as secondary glio-
blastoma display aberrant methylation in multiple gene promoters (CpG
island methylator phenotype) and much less in primary glioblastomas
[5]. However, RANK/TNFRSF11A promoter methylation cannot be
attributed to the CpG island methylator phenotype alone because no
significant correlation between IDH1mutation and RANK/TNFRSF11A
promoter methylation was observed (Fisher exact test, P = 1.0).
A functional role of the observed CpG island methylation in
the transcriptional regulation of RANK/TNFRSF11A in gliomas is
Figure 4. Focus formation assay and flow cytometric analysis of U373MG glioblastoma cells transfected with RANK/TNFRSF11A or control
vector pcDNA4/myc-His. Representative image of a focus assay of U373MG and A172 cells. Number of foci formed after transfection with
RANK/TNFRSF11A (▪) or pcDNA4/myc-His control (□); t test, * U373MG, P< .0001; **A172, P= .0193 (A). Representative image and sum-marized results of all flow cytometric analysis showing significant induction of apoptosis (t test, P < .0001) as measured by detection of
cleaved PARP and analysis of phospho(Ser10)-histone H3 in U373MG cells transiently cotransfected with RANK-pcDNA4/myc-His plasmid
and pMAX GFP or pcDNA4/myc-His control vector and pMAX GFP (B).
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supported by the demonstration of reduced RANK/TNFRSF11A
promoter methylation and increased expression in glioma cells treated
with 5-aza-2′-deoxycytidine. RANK/TNFRSF11A mRNA is ubiqui-
tously expressed in human tissues, and the protein was mainly detected
in osteoclasts, fibroblasts, B and T lymphocytes, dendritic cells, and
endothelial cells [2,9,25]. RANK/TNFRSF11A and RANKL mRNA
and protein are also expressed in normal brain tissue of mice and rat pri-
marily in astrocytes and microglia [26–28]. It is interesting to note that
several members of the downstream cascade of RANK/TNFRSF11A
are well-established target genes of malignant gliomas. In particular,
AKT and PTEN alterations are common in glioblastomas [2] and may
alter the RANK response of the affected tumor cells [8,9]. These obser-
vations further support that RANK/TNFRSF11A possesses tumor sup-
pressor properties, which may be inhibited by epigenetic silencing of the
gene. The lack of correlation between hypermethylation and survival
despite the obvious impact of RANK expression on apoptosis and focus
formation of GBM cells may be due to additional molecular alterations
that may be present in the tumors of the investigated patients and affect
the clinical course. In addition to the regulation of RANK/TNFRSF11A
expression, its activity may also be altered by the expression of the
extracellularmodulatorTNFRSF11B/OPG that serves as decoy receptor
for RANKL and inhibits RANK/TNFRSF11A signaling. In concor-
dance with a tumor suppressive function of RANK/TNFRSF11A, a
strong expression of the RANKL decoy receptor TNFRSF11B/OPG
was found to be associated with tumor invasion, nodal metastases, ad-
vanced tumor stage, and poor prognosis in gastric carcinoma patients
[29]. Interestingly, it has been shown that a small subset of glioblastoma
tissues as well as established glioblastoma cell lines expressTNFRSF11B/
OPG [30]. We analyzed OPG expression by real-time RT-PCR in our
patient cohort and did not observe any correlation between OPG ex-
pression levels and RANK methylation or expression (data not shown).
Furthermore, there are several observations indicating cell-type spe-
cific apoptotic and growth inhibitory effects of RANKL/RANK and/
or their signaling targets NF-κB and JNK [10]. Müller et al. [11] ob-
served that doxorubicin-induced apoptosis in the T-lymphoblastic
cell line CEM was prevented by a neutralizing αRANKL antibody
as well as by RANK-Fc fusion protein. The apoptotic effect in this
context was mediated by NF-κB. Bharti et al. [10] showed that the
treatment of RAW 264.7 monocyte cells with RANKL leads to in-
duction of apoptosis and suppression of cellular proliferation. The
antiproliferative effect in these cells was independent of NF-κB activa-
tion but required TRAF6 recruitment and was mediated through the
MAP-kinase JNK.
The PI3K/Akt signaling pathway, which is frequently altered in
high-grade gliomas, is influenced by RANKL/RANK, thereby affecting
cellular apoptosis and survival. Gingery et al. [31] showed that block-
ing of Akt, PI3K, or NF-κB in murine osteoclasts maintained with
RANKL resulted in cellular apoptosis. In addition, RANKL was shown
to activate Akt and its antagonist PTEN and overexpression of PTEN
can result in inhibition of Akt-induced survival [24,32].
The cytoplasmic domain of RANK/TNFRSF11A has been shown
to interact with TRAF1, 2, 3, 5, and 6 [33–35]. Our observation that
transfected variants of RANK/TNFRSF11A, lacking most of the TRAF
binding sites, were equally capable of suppressing colony formation
raises the question whether RANK/TNFRSF11A interacts with other
ligands or transmembrane proteins to promote apoptotic responses of
the cells observed in the focus formation assay and flow cytometric
analysis (data not shown).
RANK/TNFRSF11A–transfected glioma cell lines showed a significant
reduction in focus formation as well as an elevated apoptotic activity. The
multipathway reporter array analysis revealed an activation of the NF-κB
signaling pathway confirming accurate biologic activity of the construct.
Beside this established signaling pathway, we observed an impact of
RANK/TNFRSF11A expression on the activity of several other signaling
cascades known to be deregulated in glioma molecular pathogenesis.
Signaling pathways initiated by amino acid deprivation (indicated
by the AARE reporter) have already been associated with the induc-
tion of apoptosis and autophagy in vertebrate cells [36].
In addition, it is striking to note that the pathways showing the most
prominent deregulation in RANK/TNFRSF11A–transfected cells are
involved in regulation of the developmental potential or the prolifera-
tion of stem-like cells. This is especially interesting because the meth-
ylation profiling of primary stem cell–enriched glioblastoma cells that
are considered to be the drivers of tumor growth exhibits particularly
high levels of methylated RANK/TNFRSF11A alleles. These comprise
the WNT, Oct4, and HIF signaling as indicated by a significant in-
duction of respective specific target genes (TCF/LEF, Oct4, HIF ). We
also unmasked a significant down-regulation of the reporter activity of
STAT3, which has been discussed as potential target for therapy for
glioma patients [37,38]. Inhibition of STAT3 signaling pathway has
also been associated with the growth regulation and apoptosis of glioma
stem cells and medulloblastomas [39–41].
In conclusion, we identified RANK/TNFRSF11A as a novel and fre-
quent target for de novomethylation in gliomas. The increased frequency
and density of methylation in the 5′-CpG island of RANK/TNFRSF11A
in glioblastoma tissues and stem cell–enriched glioblastoma cultures
Figure 5. Reporter array analysis of 45 signaling pathways in U373MG glioblastoma cells transfected with RANK-pcDNA4/myc-His plasmid
and pcDNA4/myc-His control vector. The diagram depicts the fold change of reporter activity indicative for specific cancer-associated
signaling pathways. *Signaling pathways showing significant up-regulation or down-regulation.
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comparedwith lower-grade astrocytomas suggest a selection advantage for
cells that inactivate RANK/TNFRSF11A through DNA methylation.
Our functional in vitro results further suggest that this advantage might
be due to a significantly reduced apoptotic activity of RANK/
TNFRSF11A-silenced glioma cells. This assumption is further supported
by the multi pathway reporter array that uncovered an involvement of
RANK/TNFRSF11A in the regulation of proapoptotic signaling cascades
as well as in the regulation of stem like cells within primary glioma tissues.
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Table W1. Summary of Methylation Frequencies, Mean Methylation Levels and t Test Results of RANK/
TNFRSF11A in All Investigated Gliomas.








For t test, the mean methylation levels of all investigated glioma entities were tested against each other.
*Significant difference between the methylation levels in different WHO grades (t test): AII versus AAIII, P = .3767;
AII + AAIII versus pGBMIV, P = .026; AII + AAIII versus sGBMIV, P = .0035; and pGBMIV versus sGBMIV,
P = .046.
Figure W1. Quantitative methylation data of 156 primary glioma and all investigated cell cultures. The localization of the putative p53 and
CTCF binding sites and a GC box are indicated. The color code shows the methylation range (0%-60%).
Figure W2. Representative bisulfite sequencing analysis of 5-aza-2′-
deoxycytidine–treated and –untreated U373MG and A172 cells show-
ing demethylation within the analyzed region of RANK/TNFRSF11A.
Black lollipops indicate methylated CpG position; white lollipops,
unmethylated CpG position; no circles, uncertain because of the
low-quality sequence trace.
Figure W3. Relative transcript levels of RANK/TNFRSF11A (RANK/
TNFRSF11A/ARF1) analyzed by real-time RT-PCR in the glioblastoma
cell line U373MG after stable transfection with RANK-pcDNA4/myc-
His plasmid (▪) or control vector pcDNA4/myc-His (□).
Figure W4. mRNA expression analysis of RANK/TNFRSF11A in gliomas, glioblastoma cell lines, and normal brain tissues. This figure
shows the relative expression levels of RANK/TNFRSF11A (RANK/TNFRSF11A/ARF1) obtained by real-time RT-PCR. Results of methyla-
tion analysis by pyrosequencing are included in this figure. Black column (▪) indicates that the sample is methylated; white column (□),sample is unmethylated. Samples were scored methylated if they exceeded the two-fold SD of white matter control samples (20.3%).
